# DNA Gensee

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dna-gensee

- Industry: Biotechnology
- Headquarters: France
- Website: www.dnagensee.com
- Total disclosed funding: $0.7M
- Latest round: Series B (Jan 18, 2023)
- Investors on record: 3

## About

DNA Gensee is a molecular biology service provider specializing in DNA analysis for plant and algae-based products, ensuring quality and authenticity across multiple industries, including cosmetics and food.DNA Gensee operates in France, focusing on DNA analysis to support various industries in verifying the authenticity of raw materials and products. The company has not reported any significant pivots or changes in business strategy. Founded by a team with expertise in molecular biology, DNA Gensee has built its reputation on rigorous genetic testing. The company raised EUR 600,020 in a Series B funding round on January 18, 2023, from investors including Gaillard Partners, Famille C Venture, and StarQuest, bringing the total amount raised to EUR 600,020 and establishing a current company valuation of EUR 3.397 mn.DNA Gensee specializes in molecular biology services, focusing on DNA analysis to guarantee the authenticity and quality of plant and algae-based products utilized in cosmetics, nutraceuticals, food, and health sectors. The advanced laboratory conducts genetic testing to identify species in ingredients and finished products, catering to manufacturers in Europe and North America. Additionally, DNA Gensee engages in R&D project management, partnering with industrial clients to enhance product safety and quality. Its services are designed to tackle issues of contamination and fraud, providing clarity on product sources and integrity.In 2022, DNA Gensee generated revenue amounting to EUR 251,821.70 through B2B transactions, primarily offering DNA analyses and R&D consulting tailored to the specific needs of clients. The pricing is structured based on the complexity and scale of projects, with clients typically engaging in either one-off projects or ongoing partnerships, ensuring the authenticity and safety of their products through comprehensive analyses.Looking ahead, DNA Gensee plans to utilize the recently raised EUR 600,020 from its Series B funding to enhance its service offerings and expand its market presence. The company aims to introduce new products focused on advanced DNA testing capabilities in the coming year. Additionally, DNA Gensee is exploring opportunities for geographical expansion, particularly into select markets across Europe and North America by the end of 2024, to meet the growing demand for product authenticity and traceability in various sectors.

## Funding rounds

- Series B, Jan 18, 2023, $0.7M — StarQuest, Gaillard Partners, Famille C Venture

## Investors

- StarQuest (https://capitalatlas.ai/funds/starquest) — Series B
- Gaillard Partners — Series B
- Famille C Venture (https://capitalatlas.ai/funds/famille-c-venture) — Series B